Comparison of Urine 4-(Methylnitrosamino)-1-(3) Pyridyl-1-butanol and cotinine for assessment of active and passive smoke exposure in urban adolescents

Cancer Epidemiology Biomarkers and Prevention

Volumn 27, Issue 3, 2018, Pages 254-261

  Benowitz, Neal L ^a,b   Nardone, Natalie ^b   Jain, Shonul ^b   Dempsey, Delia A ^b   Addo, Newton ^b   Helen, Gideon St ^b   Jacob, Peyton ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3) PYRIDYL 1 BUTANOL; BIOLOGICAL MARKER; BUTANOL; COTININE; TOBACCO SMOKE; UNCLASSIFIED DRUG; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTAN-1-OL; NITROSAMINE;

ACTIVE SMOKING; ADOLESCENT; ADOLESCENT SMOKING; ADULT; AFRICAN AMERICAN; ARTICLE; COMPARATIVE STUDY; DIAGNOSIS; DIAGNOSTIC ACCURACY; ENVIRONMENTAL EXPOSURE; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICALLY UNINSURED; PASSIVE SMOKING; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH INSURANCE; SCREENING; SCREENING TEST; SMOKING; TOBACCO USE; URBAN AREA; URINE SAMPLING; YOUDEN INDEX; ANALYSIS; CALIFORNIA; CHEMISTRY; ENVIRONMENTAL MONITORING; EPIDEMIOLOGY; NEOPLASM; PROCEDURES; STATISTICS AND NUMERICAL DATA; TOBACCO; URBAN POPULATION; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; COTININE; ENVIRONMENTAL MONITORING; FEMALE; HUMANS; MALE; NEOPLASMS; NITROSAMINES; SAN FRANCISCO; SMOKING; TOBACCO; TOBACCO SMOKE POLLUTION; URBAN POPULATION; YOUNG ADULT;

EID: 85045512933     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-17-0671     Document Type: Article

References (38)

1. USDHHS. Respiratory effects in children from exposure to secondhand smoke. Washington, DC: Office of the Surgeon General; 2006.
2. Tyas SL, Pederson LL. Psychosocial factors related to adolescent smoking: a critical review of the literature. Tob Control 1998; 7: 409-20.
3. Benowitz NL, Jain S, Dempsey DA, Nardone N, St. Helen G, Jacob P III. Urine cotinine screening detects nearly ubiquitous tobacco smoke exposure in urban adolescents. Nicotine Tob Res 2017; 19: 1048-54.
4. Hukkanen J, Jacob PIII, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005; 57: 79-115.
5. SRNT. Biochemical verification of tobacco use and cessation. Nicotine Tob Res 2002; 4: 149-59.
6. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003; 3: 733-44.
7. Goniewicz ML, Havel CM, Peng MW, Jacob P III, Dempsey D, Yu L, et al. Eliminationkinetics of the tobacco-specific biomarker and lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Cancer Epidemiol Biomarkers Prev 2009; 18: 3421-5.
8. Jacob P III, Benowitz NL, Destaillats H, Gundel L, Hang B, Martins-Green M, et al. Thirdhand smoke: new evidence, challenges, and future directions. Chem Res Toxicol 2017; 30: 270-94.
9. Caraballo RS, Giovino GA, Pechacek TF, Mowery PD, Richter PA, Strauss WJ, et al. Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988-1991. JAMA 1998; 280: 135-9.
10. Homa DM, Neff LJ, King BA, Caraballo RS, Bunnell RE, Babb SD, et al. Vital signs: disparities in nonsmokers' exposure to secondhand smoke-United States, 1999-2012. MMWR Morb Mortal Wkly Rep 2015; 64: 103-8.
11. Benowitz NL, St. Helen G, Dempsey DA, Jacob P III, Tyndale RF. Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity. Pharmacogenet Genomics 2016; 26: 340-50.
12. Patel YM, Stram DO, Wilkens LR, Park SS, Henderson BE, Le Marchand L, et al. The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations. Cancer Epidemiol Biomarkers Prev 2015; 24: 119-27.
13. Zhu AZ, Renner CC, Hatsukami DK, Swan GE, Lerman C, Benowitz NL, et al. The ability of plasma cotinine to predict nicotine and carcinogen exposureis altered by differencesin CYP2A6: the influence of genetics, race, and sex. Cancer Epidemiol Biomarkers Prev 2013; 22: 708-18.
14. California Tobacco Control Program. California Tobacco Facts and Figures 2015 In: Health CDoP, editor. Sacramento, CA: California Department of Public Health. 2015.
15. Benowitz N, Goniewicz ML, Eisner MD, Lazcano-Ponce E, Zielinska-Danch W, Koszowski B, et al. Urine cotinine underestimates exposure to the tobacco-derived lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in passive compared with active smokers. Cancer Epidemiol Biomarkers Prev 2010; 19: 2795-800.
16. Goniewicz ML, Eisner MD, Lazcano-Ponce E, Zielinska-Danch W, Koszowski B, Sobczak A, et al. Comparison of urine cotinine and the tobacco-specific nitrosamine metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and their ratio to discriminate active from passive smoking. Nicotine Tob Res 2011; 13: 202-8.
17. Vogel RI, Carmella SG, Stepanov I, Hatsukami DK, Hecht SS. The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers. Biomarkers 2011; 16: 491-7.
18. Jacob P III, Havel C, Lee DH, Yu L, Eisner MD, Benowitz NL. Subpicogram per milliliter determination of the tobacco-specific carcinogen metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in human urine using liquid chromatography-tandem mass spectrometry. Anal Chem 2008; 80: 8115-21.
19. Jacob P III, Yu L, Duan M, Ramos L, Yturralde O, Benowitz NL. Determination of the nicotine metabolites cotinine and trans-3'-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 267-76.
20. Fraley C, Raferty AE. Model-based clustering, discriminant analysis and density estimation. J Am Stat Assoc 2002; 97: 611-31.
21. Fraley C, Raferty AE, Murphy TB, Scrucca L. mclust Version 4 for R. Normal mixture modeling for model-based clustering, classification, and density estimation. Seattle, WA: Department of Statistics, University of Washington; 2012.
22. Schisterman EF, Perkins NJ, Liu A, Bondell H. Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. Epidemiology 2005; 16: 73-81.
23. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3: 32-5.
24. Avila-Tang E, Al-Delaimy WK, Ashley DL, Benowitz N, Bernert JT, Kim S, et al. Assessing secondhand smoke using biological markers. Tob Control 2013; 22: 164-71.
25. Bernert JT, Pirkle JL, Xia Y, Jain RB, Ashley DL, Sampson EJ. Urine concentrations of a tobacco-specific nitrosamine carcinogen in the U.S. population from secondhand smoke exposure. Cancer Epidemiol Biomarkers Prev 2010; 19: 2969-77.
26. Schick SF, Blount BC, Jacob P III, Saliba NA, Bernert JT, El Hellani A, et al. Biomarkers of exposure to new and emerging to bacco andnicotine delivery products. Am J Physiol Lung Cell Mol Physiol 2017; 313: L425-L452.
27. Wei B, Blount BC, Xia B, Wang L. Assessing exposure to tobacco-specific carcinogen NNK using its urinary metabolite NNAL measured in US population: 2011-2012. J Expo Sci Environ Epidemiol 2016; 26: 249-56.
28. Xia Y, Bernert JT, Jain RB, Ashley DL, Pirkle JL. Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in smokers in the United States: NHANES 2007-2008. Biomarkers 2011; 16: 112-9.
29. Siegmund B, Leitner E, Pfannhauser W. Determination of the nicotine content of various edible nightshades (Solanaceae) and their products and estimation of the associated dietary nicotine intake. J Agric Food Chem 1999; 47: 3113-20.
30. California Tobacco Control Program. California Tobacco Facts and Figures 2016. Sacaramento, A: California Department of Public Health; 2016.
31. Hecht SS, Ye M, Carmella SG, Fredrickson A, Adgate JL, Greaves IA, et al. Metabolites of a tobacco-specific lung carcinogen in the urine of elementary school-aged children. Cancer Epidemiol Biomarkers Prev 2001; 10: 1109-16.
32. Benowitz NL, Bernert JT, Caraballo RS, Holiday DB, Wang J. Optimalserum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004. Am J Epidemiol 2009; 169: 236-48.
33. Benowitz NL, Dains KM, Dempsey D, Herrera B, Yu L, Jacob P III. Urine nicotine metabolite concentrations in relation to plasma cotinine during low-level nicotine exposure. Nicotine Tob Res 2009; 11: 954-60.
34. Dempsey DA, Meyers MJ, Oh SS, Nguyen EA, Fuentes-Afflick E, Wu AH, et al. Determination of tobacco smoke exposure by plasma cotinine levels in infants and children attending urban public hospital clinics. Arch Pediatr Adolesc Med 2012; 166: 851-6.
35. Research Cf HP. California health interview survey: CHIS 2014-2015 adults who smoke. Los Angeles, CA: UCLA Center for Health Policy Research; 2014.
36. Delnevo CD, Hrywna M. The relationship of cigars, marijuana, and blunts to adolescent bidi use. Public Health Rep 2006; 121: 603-8.
37. Eisner MD, Jacob P III, Benowitz NL, Balmes J, Blanc PD. Longer term exposure to secondhand smoke and health outcomes in COPD: impact of urine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Nicotine Tob Res 2009; 11: 945-53.
38. Office on Smoking and Health (US). The health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention (US); 2006.